Cancer Immunotherapy - Global Strategic Business Report

Global Cancer Immunotherapy Market to Reach $378.5 Billion by 2030

The global market for Cancer Immunotherapy estimated at US$117.5 Billion in the year 2022, is projected to reach a revised size of US$378.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2022-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$266.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cytokines & Immunomodulators segment is readjusted to a revised 14.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $32 Billion, While China is Forecast to Grow at 21.5% CAGR

The Cancer Immunotherapy market in the U.S. is estimated at US$32 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$94 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.9% and 13.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Select Competitors (Total 42 Featured) -

• Advaxis Inc.
• Amgen Inc.
• Astrazeneca
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• ELI Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Immunomedics Inc.
• Janssen Global Services, LLC (Johnson and Johnson)
• Merck
• Novartis
• Pfizer
• Seattle Genetics, Inc.
• Spectrum Pharmaceuticals, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year